^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Breast Cancer
    Drug:docetaxel (Tubulin polymerization promoter, Microtubule stabilizer) +
    capecitabine (Thymidylate synthase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    02/22/2019
    Excerpt:
    XELODA (capecitabine) is a nucleoside metabolic inhibitor with antineoplastic activity indicated for...Metastatic Breast Cancer...In combination with docetaxel after failure of prior anthracycline containing therapy.
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    04/20/2012
    Excerpt:
    Capecitabine Teva in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.